Day: May 20, 2021

IRVING, Texas, May 20, 2021 (GLOBE NEWSWIRE) — For the second year in a row, HMS, a Gainwell Technologies Company, announced it has donated $20,000 to Girlstart, an organization that designs and implements innovative, high-quality STEM (science, technology, engineering, and math) education programs for young girls nationwide. Girlstart hosts programs throughout the year, including community STEM events, afterschool programs and their Girlstart Summer Camp each year. This year, HMS’ donation will help fund the 2021 Summer Camp program by providing high-quality science kits for campers to build Micro:bits. These pocket-sized computers with LED displays, microphones, speakers and sensors allow children to explore how hardware and software work together. All the materials and tools required will be shipped to campers unable to attend...

LAS VEGAS, May 20, 2021 (GLOBE NEWSWIRE) — Everi Holdings Inc. (NYSE: EVRI) (“Everi” or the “Company”), a premier provider of land-based and digital casino gaming content and products, financial technology, and loyalty solutions, today announced an agreement with Caesars Entertainment, Inc. (NASDAQ: CZR) (“Caesars”) to begin a Nevada field trial for Jackpot Xpress®, Everi’s jackpot management system, under guidelines issued by the Nevada Gaming Control Board. The trial will take place at the iconic Las Vegas Strip centerpiece, Caesars Palace. Upon final approval by the Nevada Gaming Control Board, Caesars will have the option to install Jackpot Xpress at all its Nevada properties. Caesars will also have the option to install Jackpot Xpress at all its owned and managed locations, pending further jurisdictional approvals. Jackpot...

Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma Dosed first patient with RP1 in the anti-PD1 failed NSCLC lung cancer cohort of the IGNYTE study Data update on lead programs to be provided during virtual investor event on June 3, 2021  Strengthened management team to prepare for potential commercial launch and enable further later stage development Ended fiscal year 2021 with approximately $476 million in Cash; Capitalized into second half of 2024 WOBURN, Mass., May 20, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced financial results for...

Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced publication of abstract #2501 by the American Society of Clinical Oncology (ASCO). The abstract summarizing interim data from the National Cancer Institute (NCI)-led phase 2 trial has been accepted for oral presentation at the 2021 ASCO Annual Meeting taking place June 4-8. The presentation, scheduled...

VANCOUVER, British Columbia, May 20, 2021 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (NYSE AMERICAN: GSV) (TSX: GSV) (“Gold Standard” or the “Company”) today announced plans for the 2021 exploration and development program on its vast land package in Nevada’s Carlin Trend. The program includes approximately 7,880 meters of reverse-circulation (“RC”) and core drilling over 46 holes. Drilling is anticipated to start in May 2021. (https://goldstandardv.com/site/assets/files/4499/2021_exploration_and_development_program.pdf) Exploration Focus Areas:Pinion SB Zone: 7 RC drill holes (approximately 2,350 meters) to further develop oxide mineralization at the SB Zone target. Previously released intercepts at SB Zone include: PR20-26 (77.7m of 2.24 g Au/t), PR20-30 (50.3m of 1.04 g Au/t), PC20-22 (61.1m of 1.07 g Au/t) (see November...

— New clinical data accepted for oral and e-Poster presentation at AACE — — e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting — NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29,...

MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items remaining on the books of the Company. The Company’s application for uplisting to the OTCQB had been declined due to outstanding variable rate loans which were on the Company’s financial statements at the time of the application. The Company can re-apply in October 2021. Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are in the process of getting rid of these loans to minimize dilution. Protecting the shareholders against harmful dilution is of utmost importance to the management of Sunshine...

MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 before market open on Thursday, June 3, 2021. The company’s management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time /8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 955-2173 for domestic callers or (914) 987-7949 for international callers, using conference ID: 1485513. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcast will be archived and available for replay for at least...

Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the appointment of Rain co-founder Robert Doebele, M.D., Ph.D. as president and chief scientific officer (“CSO”). As president, Dr. Doebele will play a critical role in shaping the company’s corporate strategy and operations and will continue to provide his precision oncology expertise to advance Rain’s clinical pipeline and lead the company’s research and development efforts as CSO. “It has been an honor and a joy to work closely with Bob since we founded Rain together, and I am delighted to recognize him as our new president,” said Avanish Vellanki, co-founder, chairman and chief executive...

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:William Blair’s 41st Annual Growth Stock ConferenceFireside Chat on Tuesday, June 1st at 11:40 a.m. ETJefferies Virtual Healthcare ConferenceFireside Chat on Friday, June 4th at 10:00 a.m. ETLive webcasts will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical...